Market Research Logo

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

Novavax Inc (NVAX) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights


Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax’s clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.
Novavax Inc Key Recent Developments

May 09,2018: Novavax Reports First Quarter 2018 Financial Results
Mar 14,2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer
Mar 14,2018: Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
Nov 07,2017: Novavax Reports Third Quarter 2017 Financial Results
Oct 13,2017: Novavax Announces Leadership Change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Novavax Inc - Key Facts
Novavax Inc - Key Employees
Novavax Inc - Key Employee Biographies
Novavax Inc - Major Products and Services
Novavax Inc - History
Novavax Inc - Company Statement
Novavax Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Novavax Inc - Business Description
Novavax Inc - Corporate Strategy
Novavax Inc - SWOT Analysis
SWOT Analysis - Overview
Novavax Inc - Strengths
Novavax Inc - Weaknesses
Novavax Inc - Opportunities
Novavax Inc - Threats
Novavax Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Novavax Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 09, 2018: Novavax Reports First Quarter 2018 Financial Results
Mar 14, 2018: Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer
Mar 14, 2018: Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
Nov 07, 2017: Novavax Reports Third Quarter 2017 Financial Results
Oct 13, 2017: Novavax Announces Leadership Change
Aug 08, 2017: Novavax Reports Second Quarter 2017 Financial Results
May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine
May 08, 2017: Novavax Reports First Quarter 2017 Financial Results
Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Novavax Inc, Key Facts
Novavax Inc, Key Employees
Novavax Inc, Key Employee Biographies
Novavax Inc, Major Products and Services
Novavax Inc, History
Novavax Inc, Other Locations
Novavax Inc, Subsidiaries
Novavax Inc, Joint Venture
Novavax Inc, Key Competitors
Novavax Inc, Ratios based on current share price
Novavax Inc, Annual Ratios
Novavax Inc, Annual Ratios (Cont...1)
Novavax Inc, Interim Ratios
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Novavax Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Novavax Inc, Performance Chart (2013 - 2017)
Novavax Inc, Ratio Charts
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report